ISSN: 2167-0846
Journal of Pain & Relief
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

Primumnon Nocere: Supplements As Analgesics, A Neglected Area

Jan M. Keppel Hesselink*
Professor of molecular pharmacology, University of Witten Herdecke, Netherlands
Corresponding Author : Jan M. Keppel Hesselink
Professor of molecular pharmacology
University of Witten Herdecke, Netherlands
Tel: 0031-651700527
E-mail: neuropathie7@gmail.com, jan@neuropathie.nu
Received October 30, 2013; Accepted October 31, 2013; Published November 02, 2013
Citation: Hesselink JMK (2013) Primumnon Nocere: Supplements as Analgesics, a Neglected Area. J Pain Relief 2:e116. doi: 10.4172/2167-0846.1000e116
Copyright: © 2013 Hesselink JMK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pain & Relief

Our analgesic armamentarium is rooted in pharmaceuticals. Drugs initially protected by patent, new chemical entities (NCE), molecules which never existed on earth until medical chemists synthesized them. Within the realm of this type of analgesics there are just a handful of variations: non-steroidal anti-inflammatory drugs (NSAID’s such as ibuprofen), opioids (tramadol, oxycontin), antidepressants (amitriptyline, venlafaxin), anti-epileptics (gabapentine, pregabalin), paracetamol/acetaminophen and a waste basket of various old coanalgesics such as baclofen. Cannabinoids are for the courageous pain physicians only, although there are many safety reasons to prefer Cannabinoids over opiates.
Our approach to treatment of pain is very much dictated by efficacy data from RCT’s, the meta-analysis based on these trials, and on the Numbers Needed to Treat (NNT), an efficacy derived parameter. How different our approach would be if we selected treatments not based on efficacy plots but on the ‘Likelihood to be helped or harmed (LHH)’. This is a number based both on the Numbers Needed to Treat (NNT) as well as on the Numbers Needed to Harm (NNH). Without going into the science of calculus, just as a simple physician, I would propose to redefine the ‘Likelihood to be helped or harmed’ as the simple quotient of NNH/NNT. The highest quotient would be preferable, in line with one of the medical axiomata: Primumnon nocere, the Latin phrase that means “first, do no harm.”
Let us first take amitriptyline. Based on literature amitriptyline has a NNT of 4.6 and a NNH of 4.1. The ratio would be 4.1/4.6 makes 0.89 [1]. For Serotonin noradrenaline reuptake inhibitors the NNT is 5.1, and the NNH 16; the ratio would be 3.1 [2].
If we consider alpha-lipoic acid (ALP), a compoundregistered in Germany as drug for neuropathic diabetic pain, the NNT for 600 mg ALP/day is 2.7. As the number of adverse events was not significantly different than placebo, let us define the NNH conservatively as 100 [3]. The ratio ALP would then be 37. Let us now take a second supplement with proven efficacy and safety, palmitoylethanolamide (PEA). A natural compound we often use in our clinic for neuropathic pain, either as a standalone therapy, or as part of a multimodal approach [4]. This endogenous lipid has been explored for its analgesic properties since 35 years. Based on a clinical trial in 636 sciatic patients [5], PEA is in the same ball park as ALP, with NNT below 2 and NNH conservatively defined as 100 [6]. The ration would be approximately 50. Both quotients are far out better compared to the 0.89 and 3.1 of the tricyclic antidepressants.
Palmitoylethanolamide, alpha-lipoic acid and other molecules from the class of dietary supplements are not generally seen as analgesics. There are much more compounds in this forgotten or neglected class, for instance curcumin (diferuloylmethane), a component of turmeric (Curcuma longa). This has been referred to as very inexpensive, orally bioavailable and highly safe in humans. The compound is able to block the action and production of TNF-α in vitro model, in animal models and in humans. Curcumin is much cheaper compared to the manmade infliximab’s ($15 000-20 000 per person per year) and Aggarwal et al. boldly state: “With health-care costs and safety being major issues today, this golden spice (Curcuma) may help provide the solution” [7].
Natural compounds, even with higher NNTs, deserve to be considered more often for our patients suffering from pain. We should not focus only on pharmaceuticals and efficacy, but also on analgesic supplements and safety.
References
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acupuncture
Disc Acute Pain
Disc Advances in Anesthesia
Disc Analgesics
Disc Anesthesia
Disc Anesthesia & Critical Care
Disc Anesthesia Drugs
Disc Anesthesia Side Effects
Disc Anesthetics
Disc Arthroscopy
Disc Cancer Rehabilitation
Disc Cardiopulmonary Rehabilitation
Disc Cardiothoracic Anesthesia
Disc Cardiovascular Disability
Disc Chronic Back Pain
Disc Chronic Pain
Disc Clinical Anesthesia
Disc Clinical Physical Medicine & Rehabilitation
Disc Dental Anesthesia
Disc End of Life Care
Disc Epidural Anesthesia
Disc Ethics in Palliative
Disc Euthanasia
Disc Family Caregiver
Disc General Anesthesia
Disc Geriatric Care
Disc Geriatric Rehabilitation
Disc Home Care
Disc Hospice Care
Disc Hospice Palliative Care
Disc Hospice and Palliative Medication
Disc Hypnosis
Disc Inpatient Rehabilitation
Disc Interventional Pain
Disc Local Anesthesia
Disc Low Back Pain
Disc Meditation
Disc Mental Rehabilitation
Disc Musculoskeletal Pain Management
Disc Natural Pain Relievers
Disc Nerve Blocks
Disc Neuromuscular Medicine
Disc Nociceptive Pain
Disc Obstetric Anesthesiology
Disc Old Age Care
Disc Opioid
Disc Orthopedic Rehabilitation
Disc Orthopedics
Disc Pain Medication
Disc Pain Medicine
Disc Pain Sensation
Disc Pain Tolerance
Disc Pain killer drugs
Disc Palliative Care
Disc Palliative Care Drugs
Disc Palliative Care Medications
Disc Palliative Care Nursing
Disc Palliative Care and Euthanasia
Disc Palliative Medicare
Disc Palliative Neurology
Disc Palliative Oncology
Disc Palliative Psychology
Disc Palliative Sedation
Disc Palliative Surgery
Disc Palliative Treatment
Disc Pediatric Anesthesiology
Disc Pediatric Palliative Care
Disc Pediatric Rehabilitation
Disc Physical Medicine and Rehabilitation
Disc Physical Therapist Communications
Disc Post-Operative Pain
Disc Reaction to Pain
Disc Regional Anesthesia
Disc Rehabilitation Nursing
Disc Rehabilitation Services
Disc Rehabilitation Therapy
Disc Sedation
Disc Spinal Anesthesia
Disc Spinal Cord Injury Medicine
Disc Surgical Anesthesia
Disc Surgical Rehabilitation
Disc Traumatic Brain Injuries (TBI)
Disc Vascular Anesthesia
Disc Volunteer Palliative Care
 
Recommended Journals
Disc Journal of Palliative Care & Medicine
Disc International Journal of Physical Medicine & Rehabilitation
Disc Journal of Anesthesia & Clinical Research
  View More»
 
Recommended Conferences
Disc 5th Global Pharmacists Conference
Jul 14-16, 2016, Brisbane, Australia
Disc  Neurorehabilitation Conference
July 21-22, 2016 Brisbane, Australia
Disc Conference Pain Research  
Oct 6-8, 2016, Vancouver, Canada
Disc Pain Management Conference   
Oct 06-08, 2016, Vancouver, Canada
View More»
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11170
  [From(publication date):
December-2013 - Jun 28, 2016]
  Breakdown by view type
  HTML page views : 7437
  PDF downloads :3733
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version